- CH₣311.46bn
- CH₣337.55bn
- CH₣61.52bn
Brief: Roche Reports Positive Phase II Results For Enicepatide
Brief: European Commission Approves Roche’s Susvimo For Treatment Of Neovascular Age-Related Macular Degeneration
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Anthropic quietly sets up biology lab as it ramps AI drug program
Brief: CHMP Recommends EU Approval Of Roche's Ocrevus For Children And Adolescents
Anthropic quietly sets up biology lab as it ramps AI drug program
Corrected: TABLE-Swiss trade surplus at CHF 4.35 bln in August (Sept. 17)
Brief: Roche Says Phase III Celestimo Study Meets Primary Endpoint In Follicular Lymphoma
US FDA extends review of Exelixis' cancer drug (updated)
Brief: U.S. FDA Grants Priority Review For Roche’S Enspryng For Mogad
Europe Research Roundup: AstraZeneca, GSK, Kingspan Group
Roche's sustained growth visibility, Novartis' execution risks - RBC initiates coverage
Swiss stocks - Factors to watch on September 9
Ultragenyx hits record low after rare disease drug trial failure
Ultragenyx Pharma plunges after rare disease drug trial failure
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660